查看“免疫检查点耐药”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[免疫检查点耐药]]</strong> 是指恶性肿瘤在接受免疫检查点抑制剂（ICIs，如 PD-1/PD-L1、CTLA-4 抑制剂）治疗过程中，通过多种机制避开免疫系统的识别与攻击。耐药可分为 <strong>[[原发性耐药]]</strong>（患者从未产生临床获益）和 <strong>[[继发性耐药]]</strong>（患者在有效应答后出现进展）。耐药机制涉及肿瘤细胞内在基因突变、<strong>[[肿瘤微环境]]</strong>（TME）的免疫抑制重塑以及宿主全身代谢状态。破解耐药难题是当前精准肿瘤学提升免疫治疗获益率的核心挑战。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden; float: right; margin-left: 20px; margin-bottom: 20px;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">免疫检查点耐药</div>
            <div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">Immune Checkpoint Resistance (点击展开)</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 20px; text-align: center; background-color: #f8fafc;">
                <div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 12px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
                    <div style="width: 100px; height: 100px; background: #f1f5f9; border-radius: 4px; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.7em;">Resistance Mechanism</div>
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 10px; font-weight: 600;">[[肿瘤免疫逃逸]] 模型图</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.82em;">
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">耐药分类</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">原发性, 继发性</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">关键驱动基因</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">B2M, JAK1/2, STK11</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">抑制性细胞</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">MDSCs, Tregs, TAMs</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">耐药标志物</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;">低 TMB, 载脂蛋白 E</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">新兴靶点</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">LAG-3, TIM-3, TIGIT</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">相关疗法</th>
                    <td style="padding: 8px 12px; color: #b91c1c;">ADC, 溶瘤病毒, 联合用药</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心机制：肿瘤“逃逸”的多重路径</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        免疫检查点耐药是动态且复杂的生物学过程，主要通过以下三大维度实现：
    </p>

    

    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>肿瘤细胞内在因素：</strong>
            <ul style="margin-top: 6px;">
                <li><strong>抗原呈递缺陷：</strong> <strong>[[B2M]]</strong> 缺失导致 MHC-I 类分子无法在膜表面稳定，使得 T 细胞无法“看见”肿瘤。</li>
                <li><strong>信号通路突变：</strong> <strong>[[JAK1/2]]</strong> 突变导致肿瘤对干扰素（IFN-gamma）信号失去响应，无法产生有效的免疫激活反馈。</li>
                <li><strong>抑癌基因缺失：</strong> 如 <strong>[[STK11/LKB1]]</strong> 缺失常与“冷肿瘤”（T 细胞排斥型微环境）高度相关。</li>
            </ul>
        </li>
        <li style="margin-bottom: 12px;"><strong>肿瘤外在因素（微环境重塑）：</strong>
            <ul style="margin-top: 6px;">
                <li><strong>抑制性细胞浸润：</strong> <strong>[[髓源性抑制细胞]]</strong>（MDSCs）和调节性 T 细胞（Tregs）通过分泌 IL-10 或 TGF-beta 强力压制效应 T 细胞。</li>
                <li><strong>代谢剥夺：</strong> 肿瘤细胞快速消耗葡萄糖并产生乳酸，导致低 pH 环境，直接抑制 T 细胞的功能活性。</li>
            </ul>
        </li>
        <li style="margin-bottom: 12px;"><strong>免疫检查点代偿上调：</strong>
            <ul style="margin-top: 6px;">
                <li>当 PD-1 被阻断后，肿瘤可能通过上调 <strong>[[LAG-3]]</strong>、TIM-3 或 VISTA 等其他“免疫制动器”来产生逃逸，这是继发性耐药的主要原因。</li>
            </ul>
        </li>
    </ul>

    <h2 style="background: #fff1f2; color: #9f1239; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: #9f1239 6px solid; font-weight: bold;">临床耐药分类及应对策略</h2>
    
    <div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.88em; text-align: center;">
            <tr style="background-color: #eff6ff; color: #1e40af;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; width: 25%;">耐药模式</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; width: 25%;">病理特征</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; width: 50%;">克服策略（临床进展）</th>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[原发性耐药]]</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">免疫荒漠型/冷肿瘤</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; text-align: left; background-color: #fdf2f2;">联合 <strong>[[抗血管生成药]]</strong> 或局部放疗，旨在“加热”肿瘤，促进 T 细胞浸润。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[继发性耐药]]</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">抗原丢失/检查点转换</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; text-align: left;">换用新型双特异性抗体（如 PD-1/CTLA-4 双抗）或 <strong>[[ADC]]</strong> 药物直接杀伤。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[假性进展]]</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; color: #b91c1c;">影像学增大，实则好转</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; text-align: left;">需结合临床症状及 <strong>[[ctDNA]]</strong> 动态变化进行鉴别，不应轻易判定为耐药。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f0fdf4; color: #166534; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: #166534 6px solid; font-weight: bold;">针对耐药的精准干预前沿</h2>
    <div style="background-color: #f0fdf4; border-left: 5px solid #22c55e; padding: 15px 20px; margin: 20px 0; border-radius: 4px;">
        <h3 style="margin-top: 0; color: #14532d; font-size: 1.1em;">重塑免疫微环境</h3>
        <ul style="margin-bottom: 0; color: #334155; font-size: 0.95em;">
            <li><strong>[[多靶点联合]]：</strong> 针对 PD-1 耐药患者，联合 <strong>[[LAG-3 抑制剂]]</strong>（如 Relatlimab）已在临床中被证实能有效逆转 T 细胞耗竭状态。</li>
            <li style="margin-top: 10px;"><strong>[[表观遗传重塑]]：</strong> 探索 HDAC 抑制剂与免疫治疗联用，通过改变染色质状态，重新诱导肿瘤抗原及 MHC 分子的表达。</li>
            <li style="margin-top: 10px;"><strong>[[肠道微生物调节]]：</strong> 研究发现 <strong>[[粪便微生物移植]]</strong>（FMT）可重置宿主免疫阈值，部分耐药患者在接受健康捐赠者的 FMT 后恢复了对 PD-1 的应答。</li>
        </ul>
    </div>

    <h2 style="background: #f8fafc; color: #334155; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: #64748b 6px solid; font-weight: bold;">核心相关概念</h2>
    <ul style="padding-left: 25px; color: #334155; font-size: 0.95em;">
        <li><strong>[[T 细胞耗竭]]：</strong> T 细胞在长期抗原刺激下失去效应功能的状态，耐药的核心细胞学基础。</li>
        <li><strong>[[肿瘤突变负荷]] (TMB)：</strong> 预测免疫应答的重要指标，低 TMB 常伴随原发性耐药。</li>
        <li><strong>[[假性进展]]：</strong> 免疫特有的疗效评估难点，由于炎症浸润导致的病灶暂时性增大。</li>
    </ul>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评 [Academic Review]</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Sharma P, et al. (2017).</strong> <em>Primary, adaptive, and acquired resistance to cancer immunotherapy.</em> <strong>[[Cell]]</strong>.<br>
            <span style="color: #475569;">[奠基综述]：系统定义了免疫耐药的三大时序类别，确立了研究框架。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Gide TN, et al. (2019).</strong> <em>Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma.</em> <strong>[[Clinical Cancer Research]]</strong>.<br>
            <span style="color: #475569;">[临床权威]：详细论述了黑色素瘤模型中 B2M 和 JAK 突变引发的耐药图谱。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [3] <strong>Academic Review (Recent).</strong> <em>Emerging strategies to overcome immune checkpoint blockade resistance.</em> <strong>[[Nature Reviews Drug Discovery]]</strong>.<br>
            <span style="color: #475569;">[前沿进展]：总结了下一代检查点抑制剂及代谢调节剂在克服耐药中的临床表现。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            免疫检查点耐药 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">[[机制分类]]</td>
                <td style="padding: 10px 15px; color: #334155;"><strong>[[抗原丢失]]</strong> • 信号反馈中断 • 代谢拮抗</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">[[核心变量]]</td>
                <td style="padding: 10px 15px; color: #334155;">[[PD-L1 表达动态]] • HLA 杂合性丢失 • T 细胞表型转换</td>
            </tr>
            <tr>
                <td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">[[临床对策]]</td>
                <td style="padding: 10px 15px; color: #334155;">[[抗血管生成联用]] • 溶瘤病毒激活 • 肠道菌群移植</td>
            </tr>
        </table>
    </div>

</div>